Very excited about dur-928. another condition to be indicated that they're not ready to discuss. Bio markers if move will send us in the spot light with just a single dose.
Posimir it is my feeling they want to partner this soon. So the partner gets to have a great marketing advantage. Remoxy pain wants to partner. Data against Purdue next week. My assumption is with a growing field in 505-b2 drugs this will call for OxyContin to come off the market.
Posimir the market reacted to the news. Seems it determined it was a minor setback. NDA is a slam dunk on Remoxy. DUR-928 speculation could send this up 5-10 fold down the road. Should get positive news on single dose in Nash patients. Wild card ZGNX partnering Relday, I think we'll get Orient Pharma data on ADHD phase 3 trial in September. long strong
In the last call they said money is not an issue for the phase 3. We'll get more clarity at the end of the month. There should be a dur-928 trial starting soon and data from the Nash single dose this quarter. It's for safety but if it show efficacy it's a home run one (not expecting it to be). Also the PDUFA for Remoxy will be announced this month according to pain.